Literature DB >> 27446380

A novel alternative splicing isoform of NF2 identified in human Schwann cells.

Fang Su1, Zhengguang Zhou1, Wen Su1, Zishu Wang1, Qiong Wu1.   

Abstract

Vestibular schwannoma (VS) is a benign, slow-growing cranial tumor that originates from the hypertrophy of Schwann cells. The majority of sporadic VS are unilateral, and the mechanisms underlying VS tumorigenesis are not fully understood. The human neurofibromin 2 (NF2) gene encodes the tumor suppressor protein merlin and the NF2 transcript can be alternatively spliced to form numerous isoforms. The present study investigated human Schwann cells (HSCs) at the mRNA and protein level to understand the function of the alternative splicing (AS) isoform of NF2. The total RNA of HSCs was isolated and the full-length coding sequence of NF2 was amplified. The amplified products were excised from agarose gels, purified and sequenced. NF2 at a protein level was assayed by immunoprecipitation and western blot analysis. The full-length and spliced NF2 forms were amplified by polymerase chain reaction (PCR) from the HSC complementary DNA and ligated into eukaryotic expression vector pcDNA3.1(+). The plasmids were transfected into the HSC HEI-193 cell line and cell proliferation assays were performed using Cell Counting Kit-8. PCR analysis using HSC total RNA as a template revealed the presence of a shortened NF2 transcript, which was due to splicing at the 3'-end of the NF2 mRNA. Sequence analysis confirmed that this AS isoform omitted exons 11, 12, 13, 14, 15 and 16. Immunoprecipitation and western blot analysis demonstrated that the AS isoform was highly expressed in the HSCs at 38 kDa, while the wild-type (WT) isoform, which was expected at 66 kDa, was undetectable. Transfection and cell proliferation assays revealed that the WT isoform exhibited significant growth inhibition, while the AS isoform did not suppress cell growth. In conclusion, the present study detected AS NF2 isoforms in HSC for the first time, and investigated the function of the principle AS isoform. The present study suggests that although HSCs have an undetectable level of WT isoform of the NF2 protein merlin, they are not merlin-null, since they express the AS isoform. Although the AS merlin isoform has no suppressive effect on cell growth, certain mechanisms may exist that underlie this phenomenon, and this may be associated with the genesis and development of VS.

Entities:  

Keywords:  NF2; alternative splicing; human Schwann cells; vestibular schwannoma

Year:  2016        PMID: 27446380      PMCID: PMC4950834          DOI: 10.3892/ol.2016.4685

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  24 in total

1.  NF2 status of meningiomas is associated with tumour localization and histology.

Authors:  J Kros; K de Greve; A van Tilborg; W Hop; H Pieterman; C Avezaat; R Lekanne Dit Deprez; E Zwarthoff
Journal:  J Pathol       Date:  2001-07       Impact factor: 7.996

2.  Multiple transcription initiation sites, alternative splicing, and differential polyadenylation contribute to the complexity of human neurofibromatosis 2 transcripts.

Authors:  Long-Sheng Chang; Elena M Akhmametyeva; Yong Wu; Lingyun Zhu; D Bradley Welling
Journal:  Genomics       Date:  2002-01       Impact factor: 5.736

3.  The role of NF2 gene mutations and pathogenesis-related proteins in sporadic vestibular schwannomas in young individuals.

Authors:  Hongsai Chen; Xiaoman Zhang; Zhihua Zhang; Tao Yang; Zhaoyan Wang; Hao Wu
Journal:  Mol Cell Biochem       Date:  2014-03-12       Impact factor: 3.396

4.  Cerebral and spinal cord tanycytic ependymomas in a young adult with a mutation in the NF2 gene.

Authors:  Yoshihiro Kuga; Hideki Ohnishi; Yuji Kodama; Shuji Takakura; Masato Hayashi; Ryokichi Yagi; Kenji Fukutome; Ken Matsushima; Kouichirou Okamoto; Katsushi Taomoto; Hitoshi Takahashi
Journal:  Neuropathology       Date:  2014-03-10       Impact factor: 1.906

5.  Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1.

Authors:  Shilpa Prabhakar; Mehran Taherian; Davide Gianni; Thomas J Conlon; Giulia Fulci; Jillian Brockmann; Anat Stemmer-Rachamimov; Miguel Sena-Esteves; Xandra O Breakefield; Gary J Brenner
Journal:  Hum Gene Ther       Date:  2013-01-30       Impact factor: 5.695

6.  Management of hearing in pediatric NF2.

Authors:  Taylor H Shepard; Debara L Tucci; Gerald A Grant; David M Kaylie
Journal:  Otol Neurotol       Date:  2012-08       Impact factor: 2.311

7.  Loss of NF2/Merlin expression in advanced sporadic colorectal cancer.

Authors:  Tamara Cačev; Gorana Aralica; Božo Lončar; Sanja Kapitanović
Journal:  Cell Oncol (Dordr)       Date:  2013-12-10       Impact factor: 6.730

8.  Functional inactivation of NF2/merlin in human mesothelioma.

Authors:  Claudio Thurneysen; Isabelle Opitz; Stefanie Kurtz; Walter Weder; Rolf A Stahel; Emanuela Felley-Bosco
Journal:  Lung Cancer       Date:  2008-10-04       Impact factor: 5.705

9.  ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy.

Authors:  Joni K Doherty; Weg Ongkeko; Brianna Crawley; Ali Andalibi; Allen F Ryan
Journal:  Otol Neurotol       Date:  2008-01       Impact factor: 2.311

10.  Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity.

Authors:  Pierig Lepont; John T Stickney; Lauren A Foster; Jin-Jun Meng; Robert F Hennigan; Wallace Ip
Journal:  Mutat Res       Date:  2007-08-06       Impact factor: 2.433

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.